Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

FDA OKs Marketing for First ADHD Med Device

The FDA has permitted marketing of a prescription-only device to treat attention deficit hyperactivity disorder.

The Monarch eTNS System / Image: Medgagdet
The Monarch eTNS System / Image: Medgagdet

For decades, the go-to treatment for attention-deficit/hyperactivity disorder (ADHD) has been a prescription for amphetamine (Adderall) or methylphenidate (Ritalin). However, a new prescription-only medical device, and first non-drug treatment, could soon be on the market to compete. According to a recent USA Today article, the Monarch external Trigeminal Nerve Stimulation (eTNS) System was just cleared for marketing by the FDA.

The Monarch eTNS System is intended for children ages 7 to 12 who are not taking ADHD prescription medication. A wire connects the device to a small patch on the forehead of the patient and generates a low-level electrical pulse to the trigeminal nerve, which relays a therapeutic signal to the part of the brain that regulates attention, emotion and behavior. Clinical trials suggest it can take up to four weeks for progress to become evident.

Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
Pharmaceutical Innovations Report
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?